Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.44 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 2/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.40 |
| ▸ | ALKBH1 | Q13686 | 3/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18397011 | 0.87 | L3MBTL1 (0.50) | L3MBTL1ALDH1A1IKBKETBK1JAK1 | |
| SCHEMBL22064000 | 0.85 | L3MBTL1 (0.49) | L3MBTL1ALDH1A1IKBKETBK1JAK1 | |
| SCHEMBL28637007 | 0.85 | L3MBTL1 (0.49) | L3MBTL1ALDH1A1IKBKETBK1JAK1 | |
| SCHEMBL22183009 | 0.85 | L3MBTL1 (0.49) | L3MBTL1IKBKETBK1JAK1JAK3 | |
| SCHEMBL23535650 | 0.85 | L3MBTL1 (0.50) | L3MBTL1HCAR3ALDH1A1IKBKETBK1 | |
| SCHEMBL2824830 | 0.84 | L3MBTL1 (0.56) | L3MBTL1CYP4F2CYP4A11HCAR3ALDH1A1 | |
| SCHEMBL370482 | 0.83 | L3MBTL1 (0.62) | L3MBTL1CYP4F2CYP4A11PLA2G4AHPGDS | |
| SCHEMBL18397398 | 0.83 | L3MBTL1 (0.46) | L3MBTL1IKBKETBK1JAK1JAK3 | |
| SCHEMBL2823114 | 0.81 | L3MBTL1 (0.49) | L3MBTL1ALDH1A1HSD17B10 | |
| SCHEMBL4240582 | 0.81 | L3MBTL1 (1.00) | L3MBTL1CYP4F2CYP4A11HCAR3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3672952-B1 | BENZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | claimed |
| EP-3661941-B1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | claimed |
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-09-29 | — | — | US | claimed |
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2022-09-27 | — | — | US | claimed |
| US-11192899-B2 | Quinoxaline derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2021-12-07 | — | — | US | claimed |
| US-11186592-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2021-11-30 | — | — | US | claimed |
| US-20200354375-A1 | QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-11-12 | — | — | US | claimed |
| US-20200207720-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2020-07-02 | — | — | US | claimed |
| EP-3672951-A1 | QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | Merck Patent GmbH (DE) | 2020-07-01 | — | — | EP | claimed |
| EP-3672952-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | Merck Patent GmbH (DE) | 2020-07-01 | — | — | EP | claimed |
| EP-3661941-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | Merck Patent GmbH (DE) | 2020-06-10 | — | — | EP | claimed |
| CN-110944994-A | Quinoxaline derivatives as adenosine receptor antagonists | 默克专利股份公司 | 2020-03-31 | — | — | CN | claimed |
| WO-2019038215-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2019-02-28 | — | — | WO | claimed |
| WO-2019038214-A1 | QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2019-02-28 | — | — | WO | claimed |
| WO-2019025099-A1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2019-02-07 | — | — | WO | claimed |
| EP-1773827-B1 | BENZOTHIAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-02-17 | — | — | EP | claimed |
| US-7371749-B2 | Benzothiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-05-13 | — | — | US | claimed |
| EP-1773827-A1 | BENZOTHIAZOLE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-18 | — | — | EP | claimed |
| US-20060019949-A1 | Benzothiazole derivatives | HOFFMANN-LA ROCHE INC. | 2006-01-26 | — | — | US | claimed |
| WO-2006008041-A1 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019949-A1 | Benzothiazole derivatives | CNR2, CNR1, CHRNA2 | L3MBTL1 1615/4885CYP4F2 566/4885CYP4A11 792/4885 |
| US-20220306588-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | L3MBTL1 3610/4885CYP4F2 2337/4885CYP4A11 2460/4885 |
| US-20200354375-A1 | QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, P2RY1 | L3MBTL1 4006/4885CYP4F2 2115/4885CYP4A11 2578/4885 |
| US-11453647-B2 | Benzimidazole derivatives as adenosine receptor antagonists | ADORA1, ADORA2A, ADORA3 | L3MBTL1 3645/4885CYP4F2 2306/4885CYP4A11 2705/4885 |
| US-11192899-B2 | Quinoxaline derivatives as adenosine receptor antagonists | ADORA2A, ADORA1, P2RY1 | L3MBTL1 4006/4885CYP4F2 2115/4885CYP4A11 2578/4885 |
| US-11186592-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | ADORA1, ADORA2A, AMPD2 | L3MBTL1 4125/4885CYP4F2 2344/4885CYP4A11 2591/4885 |
| US-20200207720-A1 | BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | ADORA1, ADORA2A, ADORA3 | L3MBTL1 3610/4885CYP4F2 2337/4885CYP4A11 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.